4582 SymBio Pharmaceuticals Limited - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4582

TSE Growth

SymBio Pharmaceuticals Limited

100

JPY

-1

(-0.99%)

Dec 5, 3:30 pm JST

0.64

USD

Dec 5, 1:30 am EST

Result

PTS

outside of trading hours

100

Dec 5, 10:36 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2021	8,256	1,016	1,001	2,032	53.0	0	Feb 10, 2022	J-GAAP
Dec, 2022	10,008	1,963	1,999	1,179	30.2	0	Feb 9, 2023	J-GAAP
Dec, 2023	5,589	-811	-736	-1,962	-49.2	0	Feb 8, 2024	J-GAAP
Dec, 2024	2,452	-3,876	-3,689	-3,833	-85.0	0	Feb 6, 2025	J-GAAP
Dec, 2025 Guidance	1,400	-4,262	-4,467	-4,592	-84.2	0	Jun 10, 2025	J-GAAP
YoY	-42.9%	-10.0%	-21.1%	-19.8%	+1.0%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2020	Feb 6, 2020	3,404	-5,090	-5,134	-4,803	0	J-GAAP
	Sep 17, 2020	3,043	-4,592	-4,656	-3,796	0	J-GAAP
Results	Feb 4, 2021	2,987	-4,506	-4,615	-4,090	0	J-GAAP
Dec, 2021	Feb 4, 2021	Available in future release
Results	Feb 10, 2022
Dec, 2022	Feb 10, 2022
	Aug 4, 2022
	Nov 8, 2022
Results	Feb 9, 2023
Dec, 2023	Feb 9, 2023
	Aug 3, 2023
	Nov 14, 2023
Results	Feb 8, 2024
Dec, 2024	Feb 8, 2024
	May 7, 2024
Results	Feb 6, 2025
Dec, 2025	Feb 6, 2025	1,858	-4,263	-4,347	-4,468	0	J-GAAP
	Jun 10, 2025	1,400	-4,262	-4,467	-4,592	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2006	0	－	Available in future release
Dec, 2007	0	－
Dec, 2008	1,630	－
Dec, 2009	1,191	-26.9
Dec, 2010	1,449	+21.7
Dec, 2011	1,882	+29.9
Dec, 2012	1,955	+3.9
Dec, 2013	1,532	-21.6
Dec, 2014	1,955	+27.6
Dec, 2015	1,933	-1.1
Dec, 2016	2,368	+22.5
Dec, 2017	3,444	+45.4
Dec, 2018	3,835	+11.4
Dec, 2019	2,837	-26.0
Dec, 2020	2,987	+5.3
Dec, 2021	8,256	+176.4
Dec, 2022	10,008	+21.2
Dec, 2023	5,589	-44.2
Dec, 2024	2,452	-56.1
Dec, 2025 Guidance	1,400	-42.9	-4,262	-10.0	-4,467	-21.1	-84.2	+0.9

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2023	5,589	-811	-15	-26.10	-21.09	0.60	-49.2
Dec, 2024	2,452	-3,876	-158	-70.86	-58.35	0.37	-85.0
Dec, 2025 Guidance	1,400	-4,262	-304	-346.57	-100.26	0.31	-84.2

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	10,008	1,963	1,999	2,032	53.0
Fiscal Year	Dec, 2022	Dec, 2022	Dec, 2022	Dec, 2021	Dec, 2021

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2022	5,135	591	552	71	1.8	0	Feb 9, 2023	J-GAAP
Jul - Dec, 2023	2,411	-762	-802	-1,883	-47.2	0	Feb 8, 2024	J-GAAP
Jul - Dec, 2024	1,168	-2,157	-2,208	-2,292	-50.8	0	Feb 6, 2025	J-GAAP
Jul - Dec, 2025 Guidance	754	-2,108	-2,127	-2,223	-40.8	0	Jul 31, 2025	J-GAAP
YoY	-35.4%	+2.3%	+3.7%	+3.0%	+19.8%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2022	1,963	1,567	1,614	-47	627	6,282	60.21	J-GAAP
Dec, 2023	-811	-570	-194	-376	680	6,517	79.77	J-GAAP
Dec, 2024	-3,876	-3,419	-3,416	-3	708	3,963	79.77	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2023	4,421	-283	-156	-788	-19.9	ー	Nov 14, 2023	J-GAAP
Jan - Sep, 2024	1,898	-2,791	-2,759	-2,845	-63.4	ー	Oct 31, 2024	J-GAAP
Jan - Sep, 2025	970	-3,339	-3,538	-3,565	-73.5	ー	Oct 30, 2025	J-GAAP
YoY	-48.9%	-19.6%	-28.2%	-25.3%	-15.8%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	1,168	-528	-580	-1,174	-29.4	-45.2	Feb 8, 2024	J-GAAP
Jan - Mar, 2024	597	-806	-727	-777	-18.0	-135.0	May 7, 2024	J-GAAP
Apr - Jun, 2024	687	-913	-754	-764	-17.2	-132.9	Aug 1, 2024	J-GAAP
Jul - Sep, 2024	614	-1,072	-1,278	-1,304	-29.1	-174.6	Oct 31, 2024	J-GAAP
Oct - Dec, 2024	554	-1,085	-930	-988	-21.9	-195.8	Feb 6, 2025	J-GAAP
Jan - Mar, 2025	264	-1,169	-1,288	-1,321	-28.0	-442.8	May 8, 2025	J-GAAP
Apr - Jun, 2025	382	-985	-1,052	-1,048	-21.8	-257.9	Jul 31, 2025	J-GAAP
Jul - Sep, 2025	324	-1,185	-1,198	-1,196	-24.6	-365.7	Oct 30, 2025	J-GAAP
YoY	-47.2%	-10.5%	+6.3%	+8.3%	+15.2%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	655	-21.0	Available in future release
Jan - Mar, 2021	1,420	+157.7
Apr - Jun, 2021	1,726	+113.3
Jul - Sep, 2021	2,407	+147.6
Oct - Dec, 2021	2,703	+312.7
Jan - Mar, 2022	2,315	+63.0
Apr - Jun, 2022	2,558	+48.2
Jul - Sep, 2022	2,482	+3.1
Oct - Dec, 2022	2,653	-1.8
Jan - Mar, 2023	1,544	-33.3
Apr - Jun, 2023	1,634	-36.1
Jul - Sep, 2023	1,243	-49.9
Oct - Dec, 2023	1,168	-56.0
Jan - Mar, 2024	597	-61.3
Apr - Jun, 2024	687	-58.0
Jul - Sep, 2024	614	-50.6
Oct - Dec, 2024	554	-52.6
Jan - Mar, 2025	264	-55.8
Apr - Jun, 2025	382	-44.4
Jul - Sep, 2025	324	-47.2	-1,185	-10.5	-1,198	+6.3	-24.6	+15.5

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	2,703	863	969	1,708	44.6
Fiscal Year	Dec, 2021	Jun, 2022	Jun, 2022	Dec, 2021	Dec, 2021

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2022	204.83	77.6	10,433	8,094	-26,889	ー	Feb 9, 2023	J-GAAP
Dec, 2023	164.32	84.9	8,170	6,938	-28,852	ー	Feb 8, 2024	J-GAAP
Dec, 2024	84.66	78.1	4,968	3,880	-32,685	ー	Feb 6, 2025	J-GAAP
Jan - Sep, 2025	ー	28.9	4,580	1,325	-36,251	1.77	Oct 30, 2025	J-GAAP

SymBio Pharmaceuticals Limited(4582) Financial Results